WithdrawnPhase 2NCT00148980
Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation
Studying Myelodysplastic/myeloproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hadassah Medical Organization
- Principal Investigator
- Olga Gurevitch, PhDHadassah Medical Organization
- Intervention
- DBM for creation of bone marrow microenvironment(device)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2003
Study locations (1)
- Hadassah Medical Organization, Jerusalem, Israel
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00148980 on ClinicalTrials.govOther trials for Myelodysplastic/myeloproliferative disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06532084Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT05788679A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDSKarolinska University Hospital
- RECRUITINGPHASE2NCT04493164CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center
See all trials for Myelodysplastic/myeloproliferative disease →